Q3 Earnings Forecast for KALA BIO Issued By Lifesci Capital

Key Points

• Analysts at Lifesci Capital have projected KALA BIO's Q3 2025 earnings to be at (1.02) per share, with a consensus estimate for the full-year earnings at (10.84) per share.
• KALA BIO's stock recently surged 400% in the past month, currently trading around $14.53, while institutional investors hold 24.61% of its shares.
• Insider trading activity has seen Director Mark T. Iwicki sell 13,227 shares at an average price of $4.01, decreasing his position in the company.

KALA BIO, Inc. (NASDAQ:KALA - Free Report) - Investment analysts at Lifesci Capital issued their Q3 2025 earnings estimates for KALA BIO in a report issued on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois expects that the company will earn ($1.02) per share for the quarter. Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for KALA BIO's current full-year earnings is ($10.84) per share. Lifesci Capital also issued estimates for KALA BIO's Q4 2025 earnings at ($1.11) EPS, FY2025 earnings at ($4.94) EPS, Q1 2026 earnings at ($1.14) EPS, Q2 2026 earnings at ($1.17) EPS, Q3 2026 earnings at ($1.26) EPS, Q4 2026 earnings at ($1.29) EPS and FY2026 earnings at ($4.87) EPS.

Several other equities analysts have also commented on the stock. Oppenheimer reiterated an "outperform" rating and issued a $15.00 price target on shares of KALA BIO in a research note on Monday, June 2nd. HC Wainwright dropped their price target on shares of KALA BIO from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, May 23rd. Mizuho initiated coverage on shares of KALA BIO in a research note on Monday. They issued an "outperform" rating and a $30.00 price target on the stock. LADENBURG THALM/SH SH initiated coverage on KALA BIO in a report on Friday, July 11th. They issued a "buy" rating and a $12.00 price objective for the company. Finally, Wall Street Zen downgraded KALA BIO from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $17.25.

KALA BIO Stock Up 6.9%

KALA BIO stock traded up $0.97 during mid-day trading on Friday, hitting $14.97. The company had a trading volume of 91,273 shares, compared to its average volume of 103,099. The stock has a market cap of $105.06 million, a price-to-earnings ratio of -2.19 and a beta of -1.81. KALA BIO has a 1 year low of $2.92 and a 1 year high of $15.80. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 3.19. The business has a fifty day moving average of $8.16 and a 200 day moving average of $5.91.

KALA BIO (NASDAQ:KALA - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($1.71) EPS for the quarter, beating the consensus estimate of ($1.82) by $0.11.

Institutional Investors Weigh In On KALA BIO

Several hedge funds have recently modified their holdings of the stock. AIGH Capital Management LLC lifted its holdings in shares of KALA BIO by 52.8% during the second quarter. AIGH Capital Management LLC now owns 300,000 shares of the company's stock worth $1,428,000 after purchasing an additional 103,650 shares during the period. ADAR1 Capital Management LLC lifted its holdings in shares of KALA BIO by 35.7% during the first quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company's stock worth $1,713,000 after purchasing an additional 78,582 shares during the period. Woodline Partners LP acquired a new stake in shares of KALA BIO during the first quarter worth $1,483,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of KALA BIO by 10.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 178,934 shares of the company's stock valued at $1,242,000 after buying an additional 16,271 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock valued at $268,000 after buying an additional 1,534 shares in the last quarter. 24.61% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at KALA BIO

In related news, Director Mark T. Iwicki sold 13,227 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $4.01, for a total transaction of $53,040.27. Following the completion of the sale, the director directly owned 258,433 shares of the company's stock, valued at $1,036,316.33. This trade represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 30,678 shares of company stock worth $123,019 over the last three months. 8.32% of the stock is owned by company insiders.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.